

VistaSeq Breast and GYN Cancer

Order Name: **Breast/GYN Ca**
Test Number: 5194365
Revision Date: 01/01/2025

TEST NAME	METHODOLOGY	LOINC CODE
VistaSeq Breast and GYN Cancer	See Test Notes	

SPECIMEN REQUIREMENTS				
Specimen	Specimen Volume (mL)	Specimen Type	Specimen Container	Transport Environment
Preferred	10 mL (7 mL)	Whole Blood	EDTA (Lavender Top)	Room Temperature
Alternate 1	10 mL (7 mL)	Whole Blood	ACD Solution A or B (Yellow Top)	Room Temperature
Alternate 2	2 mL (0.5 mL)	Saliva	See Instructions	Room Temperature
Instructions	<p>Notes: 7 mL whole blood, 0.5 mL saliva</p> <p>Specimen Type: Lavender-top (EDTA) tube OR yellow-top (ACD) tube OR Oragene DX 500 saliva collection kit.</p> <p>Specimen Storage: Room temperature</p> <p>Specimen Collection: Blood is collected by routine phlebotomy. Saliva is collected by spitting into the provided container until it reaches the fill line.</p> <p>Special Instructions: A clinical questionnaire should be submitted with all specimens. Contact CMBP genetic services at 800-345-4363 to coordinate testing.</p> <p>Specimen Stability: Ambient: 60 days, Refrigerated : 60 days, Frozen: Not Available</p> <p>Causes for Rejection: Frozen specimen; leaking tube; clotted specimen; grossly or hemolyzed specimen; quantity not sufficient for analysis; incorrect anticoagulant; saliva collection in an incorrect container. Do not eat, drink, smoke, or chew gum 30 minutes prior to saliva sample collection. See Oragene Dx 500 saliva kit for detailed instructions.</p>			

GENERAL INFORMATION	
Expected TAT	24 - 28 days
Clinical Use	<p>Test Includes: ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, FANCC, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, NF1, PALB2, PMS2, PTEN, RAD50, RAD51C, RAD51D, STK11 and TP53.</p> <p>?Synonyms:</p> <p>Familial Cancer testing</p> <p>Hereditary Cancer testing</p> <p>Inherited Cancer testing</p>
Notes	<p>Labcorp Test Code: 481341</p> <p>Methodology: The coding region and flanking splice sites are analyzed by NGS (+/-10bp) and deletion/duplication analysis. Exon-level deletions/duplications are assessed by aCGH or by MLPA. Analysis is limited to deletion/duplication testing for EPCAM. Analysis is expanded for BRCA1/2 flanking splice sites (+/-20bp) and to include promoter sequence variants for PTEN (c.-1300 to c.-750). Clinically significant findings are confirmed by Sanger sequencing or qPCR. Results are reported using ACMG guidelines and nomenclature recommended by the Human Genome Variation Society (HGVS).</p> <p>Click Here to view on Labcorp test directory</p>
CPT Code(s)	81432
Service Provided By	